Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YH32367 |
Synonyms | |
Therapy Description |
YH32367 (ABL105) is a bispectific antibody targeting ERBB2 (HER2) and TNFRSF9 (4-1BB), which potentially enhances antitumor immune response and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1139). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YH32367 | YH 32367|YH-32367|ABL105|AB L105|AB-L105 | HER2 (ERBB2) Antibody 76 TNFRSF9 Antibody 32 | YH32367 (ABL105) is a bispectific antibody targeting ERBB2 (HER2) and TNFRSF9 (4-1BB), which potentially enhances antitumor immune response and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1139). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05523947 | Phase Ib/II | YH32367 | Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor | Recruiting | AUS | 1 |